---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007475"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:09:24.398127+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroBo Q1 net loss $6.7M; first patient dosed in DA-1726 obesity trial

## Summary
- Net loss of $6.7M ($1.32 per share) vs $2.6M ($0.51) in Q1 2023; R&D spend rose to $4.9M from $0.6M.
- Cash $16.0M as of March 31, 2024, down from $22.4M at year-end 2023; expects runway into Q4 2024.
- First patient dosed in Phase 1 SAD part of DA-1726 for obesity; top-line SAD data expected Q3 2024.
- Phase 2a trial of DA-1241 for MASH fully enrolled in Part 1; Part 2 with sitagliptin enrolling; top-line data expected Q4 2024.
- Appointed Marshall Woodworth as CFO (previously acting); exploring financing alternatives.

## SEC filing metadata
- accession: 0001558370-24-007475
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/0001558370-24-007475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/nrbo-20240509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007475
- JSON: https://secwatch.observer/filing/0001558370-24-007475.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007475.txt

## Key facts
- Earnings Releases
  MetaVia Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, NeuroBo Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and providing a corporate strategic update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837024007475/0001558370-24-007475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.